This article is more than 5 years old. Information may no longer be current.

Iluvien receives marketing authorization in Belgium

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Belgian Federal Agency for Medicines and Health Products has granted marketing approval for Iluvien to treat impaired vision associated with chronic diabetic macular edema, according to a press release from Alimera Sciences.

With this approval, Iluvien (fluocinolone acetonide intravitreal implant) is now approved for marketing in 12 countries: Austria, Belgium, Denmark, France, Germany, Italy, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States.

“With the marketing approval of Iluvien in Belgium, more patients in Europe are closer to gaining access to the only long-term, multi-year sustained-release treatment for DME and the only treatment indicated for the chronic form of the disease,” Dan Myers, president and CEO of Alimera, said in the release.